News
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...
Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...
Quarterly Net Profit at Rs. 58.25 crore in March 2025 up 47.55% from Rs. 39.48 crore in March 2024. EBITDA stands at Rs. 102.52 crore in March 2025 up 76.61% from Rs. 58.05 crore in March 2024.
4don MSN
By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at ...
Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...
A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...
AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.
Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...
The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...
AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results